Gingko bioworks stock.
Share price volatility. Over the last 12 months, Ginkgo Bioworks's shares have ranged in value from as little as $1.12 up to $2.86. A popular way to gauge a stock's volatility is its "beta". DNA.US volatility (beta: 1.32) Avg. volatility (beta: 1.00) Low High. Beta is a measure of a share's volatility in relation to the market.
Ginkgo Bioworks' ( NYSE: DNA) first quarter results were something of a mixed bag, with continued progression on a number of metrics offset by rising costs and declining revenues. Ginkgo's success ...Bought 8.0 Million shares of Ginkgo Bioworks Holdings ... Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. ...Ginkgo Bioworks Holdings Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 29, 2023 7:59 p.m. EST Delayed quote $ 1.4200 0.03 2.16% After Hours …Ginkgo Bioworks Holdings Inc stock has a Growth Score of 24, Estimate Revisions Score of 29 and Quality Score of 13. Comparing Ideaya Biosciences Inc and Ginkgo Bioworks Holdings Inc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your …
Ark Invest has purchased Ginkgo Bioworks (NYSE: DNA) six times this month. Shares of Ginkgo Bioworks (NYSE: DNA) have had a disastrous 2022, with the company losing over 65% of its market ...Ginkgo Bioworks, a synthetic-biology company, is going public Friday via a $15 billion SPAC deal. Ginkgo helps drugmakers, consumer brands, and agricultural companies develop specialized microbes.Nov 9, 2023 · For its third quarter, Ginkgo's revenue fell by 17% year over year to $55 million. The company said an expected decline in schools dampened sales in its biosecurity business segment. An ...
According to the issued ratings of 5 analysts in the last year, the consensus rating for Ginkgo Bioworks stock is Hold based on the current 1 sell rating, 3 hold ratings and 1 buy rating for DNA. The average twelve-month price prediction for Ginkgo Bioworks is $3.19 with a high price target of $6.00 and a low price target of $1.25. Learn more ...
The main competitors of Ginkgo Bioworks include Krystal Biotech (KRYS), ImmunityBio (IBRX), Denali Therapeutics (DNLI), Arcellx (ACLX), Beam Therapeutics (BEAM), Revolution Medicines (RVMD), Immunocore (IMCR), Neumora Therapeutics (NMRA), Vericel (VCEL), and Recursion Pharmaceuticals (RXRX). These companies are …11 de mai. de 2021 ... If Ginkgo Bioworks was priced at the same valuation as the basket average we mentioned earlier – a ratio of 27 – their market cap would fall to ...Vivici BV, an innovative B2B ingredients startup company using precision fermentation to make animal-free dairy proteins, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Through this collaboration, Vivici will leverage Ginkgo's extensive ...In connection with the Closing, the Company will change its name to Ginkgo Bioworks Holdings, Inc. and the combined company’s shares of Class A common stock and public warrants are expected to ...
Food ingredient company Vivici has partnered with Ginkgo Bioworks to develop a range of new alternative dairy proteins created through precision fermentation, …
Jul 5, 2022 · Ark Invest has purchased more than 3.5 million shares of Ginkgo Bioworks since June 29.; The biotech company is now the fund’s 23rd largest holding. Shares of DNA stock are down over 65% year-to ...
Synthetic biology pioneer Ginkgo Bioworks agreed to go public today in a $17.5 billion SPAC deal. The Boston-based company will merge with Soaring Eagle Acquisition Corp., a blank-check firm ...Ginkgo Bioworks (DNA-3.47%) helps companies produce bio-engineered products that can be game changers in their respective industries. One example includes working with marijuana producer Cronos ...Ginkgo Bioworks Holdings Inc - Class A (NYSE:DNA) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.Under the terms of the merger agreement entered into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock. Zymergen shares will no longer be traded on Nasdaq. GinkgoClass A common stock will continue to trade on NYSE under the ticker symbol DNA.Short History of Ginkgo Bioworks Stock Coverage We first started writing about Ginkgo Bioworks back in March 2016 in an article about three nanorobot factories . Since then, we’ve written at least another half-dozen articles about the Boston-based company, which has basically turned lab R&D for designing and programming cells into a high ...It's not a stock for the faint of heart, but its ambitious vision might pay off. Wall Street Says Ginkgo Bioworks Stock Will Soar 132%, and Cathie Wood's Buying It. …Ginkgo Bioworks (DNA-7.19%) sells something very original: the large-scale design and production of organisms. And thanks to its innovations, the company has increased revenue almost 800% over the ...
The average price point forecasted by analysts for Ginkgo Bioworks Holdings Inc (DNA) is $3.38, which is $1.92 above the current market price. The public float for DNA is 1.30B, and currently, short sellers hold a 18.11% ratio of that floaft. The average trading volume of DNA on November 27, 2023 was 19.63M shares. Top 5 EV Tech …Currently, Ginkgo Bioworks Holdings Inc does not have a price-earnings ratio. Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $326.0 million with a -375.5% net profit margin. Year-over-year quarterly sales growth most recently was -44.3%. Analysts expect adjusted earnings to reach $-0.364 per share for the current fiscal year.Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 ...Nov 29, 2023 · Of the 278 institutional investors that purchased Ginkgo Bioworks stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: ARK Investment Management LLC ($158.96M), Baillie Gifford & Co. ($154.42M), Sumitomo Mitsui Trust Holdings Inc. ($65.50M), Nikko Asset Management Americas Inc. ($28.92M ... Ginkgo Bioworks ( NYSE: DNA) is a leading synthetic biology company that went public through a SPAC in 2021. A large amount of hype has surrounded Ginkgo due to its ambitions, and it managed to ...
On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal. On 27 July 2022, it was reported that Ginkgo Bioworks would acquire Bayer's Biologics Research & Development site, located in West Sacramento. Ginkgo will enter into a new multi-year platform collaboration with Bayer. Barron's 400. Research & Ratings. U.S.: NYSE. About Ginkgo Bioworks Holdings Inc. Research & Ratings. Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes ...
Contact Us U.S. markets close in 28 minutes S&P 500 +26.05(+0.57%) Dow 30 +272.05(+0.76%) Nasdaq +74.18(+0.52%) Russell 2000 1,852.18 +43.16(+2.39%) Crude Oil 74.32 -1.64(-2.16%) Gold 2,089.10... Ginkgo Bioworks originally told investors to expect full-year 2022 revenue of at least $160 million from the ... Want TheStreet’s best daily stock and investing news right in your inbox every ...Nov 27, 2023 · Headquartered in Boston, Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts ... 6 de mar. de 2023 ... The Price is Finally Right. As we mentioned earlier, Ginkgo Bioworks stock is finally trading at a simple valuation ratio (market cap/annualized ...Find real-time DNA - Ginkgo Bioworks Holdings Inc stock quotes, company profile, news and forecasts from CNN Business.All told, these milestones could add up to $144 million for Gingko. Thus, this is potentially good news for the pharmaceutical market and terrific news for Ginkgo Bioworks. In time, all of this ...A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 ...Current stock price of Ginkgo Bioworks Inc. (DNA) online. Stock quotes and charts for Ginkgo Bioworks Inc. (DNA) on the website of Just2Trade broker.The latest Ginkgo Bioworks Holdings stock prices, stock quotes, news, and DNA history to help you invest and trade smarter.
Ginkgo Bioworks Company Info. Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and ...
Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Ginkgo Bioworks Holdings Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for DNA stock stock is $1.88, which predicts an increase of 45.74%. The lowest target is $1.25 and the highest is $2.50. On average, analysts rate DNA stock stock as a sell.Ginkgo Bioworks Company Info. Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and ... According to the issued ratings of 5 analysts in the last year, the consensus rating for Ginkgo Bioworks stock is Hold based on the current 1 sell rating, 3 hold ratings and 1 buy rating for DNA. The average twelve-month price prediction for Ginkgo Bioworks is $3.19 with a high price target of $6.00 and a low price target of $1.25. Learn more ...Company profile page for Ginkgo Bioworks Inc including stock price, company news, press releases, executives, board members, and contact information Dec 1, 2023 · Which Ginkgo Bioworks insiders have been buying company stock? The following insider purchased DNA shares in the last 24 months: Shyam Sankar ($512,000.00). How much insider buying is happening at Ginkgo Bioworks? 3 days ago. Track Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A (DNA) Stock Price, Quote, latest community messages, chart, news and other stock related …Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial ...Key Insights. Significantly high institutional ownership implies Ginkgo Bioworks Holdings' stock price is sensitive to their trading actions. A total of 7 investors have a majority stake in the ...
Company profile page for Ginkgo Bioworks Inc including stock price, company news, press releases, executives, board members, and contact information17 de set. de 2021 ... The New York Stock Exchange welcomes Ginkgo Bioworks (NYSE: DNA) in celebration of its listing. To honor the occasion, Jason Kelly, CEO, ...Currently, Ginkgo Bioworks Holdings Inc does not have a price-earnings ratio. Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $326.0 million with a -375.5% net profit margin. Year-over-year quarterly sales growth most recently was -44.3%. Analysts expect adjusted earnings to reach $-0.364 per share for the current fiscal year.Instagram:https://instagram. short stock on robinhoodnyse inspforex vps providersplaces to sell ipad Ginkgo Bioworks Company Info. Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and ... mercedes benz stocksbest intro to coding course Jul 25, 2022 · Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, ... The all-stock deal values Zymergen at $300 million market capitalization, ... See the company profile for Ginkgo Bioworks Holdings, Inc. (DNA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key ... ag quote Track Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A (DNA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsWith shares of Ginkgo Bioworks (DNA-7.19%) collapsing by 63% in the last 12 months, you'd be forgiven if you thought the biotech's heyday had ended.. But for daring investors who can tolerate ...Ginkgo Bioworks (DNA): Insiders are selling Cathie Wood-backed stock. Ginkgo Bioworks (NYSE: DNA) stock price is nearing the lowest level on record as its …